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Abstract: The possible role of melanocyte as a modulator of the
inflammation and keratinocyte hyperproliferation in psoriasis has
been hypothesised but never demonstrated on experimental basis.
Aim of the present study was to assess whether plasma levels of 5-
S-cysteinyldopa (CD), a metabolite reflecting melanocyte activity,
undergo changes in association with psoriasis together with those
of typical lipid peroxidation markers thiobarbituric acid reactive
substances (TBARS). A group of 16 patients with psoriasis at
different stage as indicated by the psoriasis area and severity index
(PASI) were enrolled against an age and sex matched control
group. Both TBARS (P < 0.05) and CD (P < 0.005) levels were
higher than controls with statistical significance. After 1 month
therapy the levels of either biomarkers decreased with respect to
the starting values although with marked individual differences.
CD may represent a novel and sensitive biomarker for the follow
up of psoriasis and evaluation of the efficacy of therapeutic
regimens beyond PASI determination.
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Background
The association of oxidative stress with psoriasis is amply docu-
mented (1,2). An overproduction of reactive oxygen species over-
whelms the antioxidant capacity resulting in oxidative damage of
lipids and other cellular constituents. Increased levels of lipid per-
oxidation markers such as malondialdehyde (3) and oxidized low
density lipoprotein (4) in the tissues, elevation of the thiobarbitu-
ric reactive substances (TBARS) (5) in blood, and accumulation of
fatty acid hydroperoxides in skin scales (6) have been observed in
psoriatic patients.
Recently a key role of melanocyte in psoriasis has been pro-
posed (7): signals from central nervous system and directed to
melanocyte may affect also basal keratinocytes stimulating an
abnormal differentiation and hyperproliferation.
That melanocyte may respond to different stimuli from the
environment is shown by the immediate and delayed pigmenta-
tion developed following solar radiation (8) and other injuries
including wound healing (9). In addition to pigment production
within melanosomes and their delivery to keratinocytes, melano-
cyte is able to secrete a wide range of signalling molecules like
cytokines, neuropeptides and neurotransmitters, which are direc-
ted towards specific receptors in keratinocytes, lymphocytes, fibro-
blasts and mast cells (10).
All melanocytes with functioning tyrosinase produce 5-S-cystei-
nyldopa (CD) whose levels in serum and urine are related to the
size and pigment forming activity of the melanocyte population
(11). On the other hand CD levels in melanocytes, epidermis and
blood seem not to depend on skin type (12,13). An increase of
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CD excretion in body fluids is associated with exposure to UV-B
(14) or UV-A (15) light radiation or phototherapy (16) as well as
with pathological states, primarily melanoma, making this metab-
olite a valuable disease progression marker (17), but has more
recently been observed in diseases not involving melanocytes, like
severe renal failure with hemodialysis treatments, where the diffuse
hyperpigmentation was shown to be due to accumulation of pheo-
melanin in the skin (18,19).
Questions addressed
The study was aimed at assessing changes of CD levels in associa-
tion with psoriasis. Plasma levels of CD and TBARS were deter-
mined comparatively in a group of 16 patients with psoriasis at
different stage as indicated by the psoriasis area and severity index
(PASI) and an age and sex matched control group. In a restricted
number of patients variations of such markers following therapy
could be determined.
Experimental design
Patients
The present study was approved by the local ethics committee. All
the patients and controls gave informed written consent.
Overall, 16 patients with psoriasis (14 men, 2 women; mean
age 54.1 ± 14.8 years, range 25–79) and 15 healthy subjects
(4 men, 11 women, mean age 44.0 ± 17.9 years, range 20–76)
were enrolled in the study. Psoriasis was graded according to PASI
exhibited at the time of blood collection (mean PASI 13.3 ± 5.2,
range 7.3–26.1). Subjects were admitted only in winter and early
spring, none of them had received UV radiation or any other spe-
cific therapy for at least 1 month prior to blood collection. Both
patients and controls were not receiving any kind of medication,
namely antioxidants, vitamins, or anti-inflammatories. Blood
samples were drawn by venepuncture into vacuum tubes in the
presence of heparin. Plasma was collected by centrifugation and
stored at –80C.
Analyses of CD and TBARS plasma levels
CD was prepared as reported (20). Determination of CD levels
was performed using high-performance liquid chromatography as
previously reported (21). Malondialdeyde and related lipid peroxi-
dation products were determined using the spectrophotometric
TBARS assay according to protocols developed for plasma samples
(22). TBARS were quantified by measuring the absorbance at
532 nm. The results were expressed as lmol ⁄ l according to a stan-
dard curve prepared using 1,1,3,3-tetramethoxypropane.
Statistical significance was evaluated using Student’s test.
Results
The extent of lipid peroxidation in plasma was determined by
measuring the levels of TBARS following current methodologies
(22). Psoriatic patients exhibited a mean value of TBARS level of
15.6 ± 5.6 lm, significantly (P < 0.05) different with respect to
the controls (mean value of 11.6 ±4.0 lm) (Fig. 1a).
Analysis of CD was performed using high performance liquid
chromatography with electrochemical detection according to a well
established procedure (21). Mean value of CD in psoriatic patients
was 7.8 ± 3.2 nm, higher than that of controls of 4.9 ± 1.3 nm with
statistical significance (P < 0.005) (Fig. 1b). No correlation
between PASI and either TBARS or CD levels was observed.
In a few cases it was possible to follow patients during therapy.
Remission of the disease associated with systemic or topical treat-
ment was assessed by PASI determination (Fig. 2a). After 1 month
treatment both TBARS and CD levels decreased with respect to
the starting values although with marked individual differences
(Fig. 2b,c). In two cases values at 2–4 months could be obtained
but no significant further changes of the levels were observed
(data not shown).
Conclusions
The positive association of psoriasis with levels of lipid peroxida-
tion products like malondialdehyde and related TBARS has been
extensively reported but data are often contradictory and scattered
(5,23). Our data clearly indicate that psoriatic patients show an
increased plasma levels of TBARS with respect to controls provid-
ing further support to the association of psoriatic condition exac-
erbation with chronic oxidative stress state. In addition, the
observation that the levels of CD rise in association with psoriatic
episodes is well in line with the reported ability of arachidonic
acid metabolites resulting from phospholipases expressed in kerati-
nocytes to stimulate melanocyte via specific receptors and rise
tyrosinase activity responsible ultimately for CD production (24).
Other inflammatory mediators and metabolites including notably
histamine may as well activate tyrosinase via the cAMP pathway
(25). On this basis the increase of CD levels in blood of psoriatic
patients is likely to result from melanocyte stimulation, with tyros-
inase mediated production of dopaquinone from tyrosine and its
scavenging by cysteine. Yet, the possibility that CD may derive
from oxidative conjugation of dopa and cysteine mediated by
reactive oxygen species generated in an oxidative stress environ-
ment other than melanocyte as described in vitro (26,27) may not
be definitely ruled out.
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Figure 1. (a) TBARS and (b) CD plasma levels of psoriatic patients (n = 16)
compared to controls (n = 15) (a, P < 0.05; b, P < 0.005). d: 25th percentile; :
median;: : 75th percentile; –: minimum and maximum values.
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Figure 2. (a) PASI, (b) TBARS and (c) CD plasma levels of four psoriatic patients
A–D before (black bars) and after (open bars) 1 month therapy.
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All together our findings would enforce the view that melano-
cyte may act as a sensory and regulatory cell of skin homeostasis
as previously suggested (28,29).
Although further studies are needed to assess possible changes
of CD levels in other non-pigmentary skin disorders, the present
evidence points to CD together with oxidative stress markers as a
promising diagnostic tool for the follow up of psoriasis and evalu-
ation of the efficacy of therapeutic regimens including topical
antioxidant ⁄ anti-inflammatory treatments (30). Development of
easy to perform analytical protocols would therefore represent a
focus of future research.
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Abstract: Genetically modified mouse lines revealed that the
epidermal growth factor receptor (EGFR) is essential for the
development and homoeostasis of the epidermis and hair
follicles. However, more detailed studies have been precluded by
the shortened lifespan of Egfr knockout mice. We employed the
mouse line Wa5 (carrying a point mutation resulting in the
expression of a dominant negative receptor) to analyse the
impact of significantly reduced EGFR signalling during multi-
stage chemical skin carcinogenesis. Seven-week-old Wa5 females
and control littermates received a single application of 7,12-
dimethylbenz(a)anthracene followed by multiple applications of
12-O-tetradecanoylphorbol-13-acetate for 26 weeks. Wa5 mice
remained free of papillomas for a longer time and developed
significantly fewer tumors than control littermates. In contrast,
the mean tumor size was not different between groups. The
present data indicate that EGFR signalling contributes to tumor
growth during multi-stage chemical carcinogenesis of the skin in
mice possibly by acting as a survival factor for skin tumor cells.
Key words: carcinogenesis – epidermal growth factor receptor – mutant
mice
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Background
Activation of the epidermal growth factor receptor (EGFR) is a cen-
tral event for normal skin development and homoeostasis and its
deregulation can result in a variety of pathological conditions (1,2).
EGFR signalling was also shown to support skin tumor develop-
ment. For instance, targeted overexpression of the EGFR ligand
transforming growth factor-a in the skin of transgenic mice induces
epidermal thickening and the development of papillomas, preferen-
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